Rabin v. McClain

881 F. Supp. 2d 758, 2012 U.S. Dist. LEXIS 58441, 2012 WL 1448107
CourtDistrict Court, W.D. Texas
DecidedApril 25, 2012
DocketCivil Action No. SA-10-CV-981-XR
StatusPublished
Cited by40 cases

This text of 881 F. Supp. 2d 758 (Rabin v. McClain) is published on Counsel Stack Legal Research, covering District Court, W.D. Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Rabin v. McClain, 881 F. Supp. 2d 758, 2012 U.S. Dist. LEXIS 58441, 2012 WL 1448107 (W.D. Tex. 2012).

Opinion

ORDER

XAVIER RODRIGUEZ, District Judge.

Before the Court is Plaintiff Eleanor Z. Rabin’s motion for default judgment. After due consideration of the relevant law, the Court GRANTS the motion and ENTERS default judgment against Defendants Douglas A. McClain Sr., Douglas A. McClain Jr., James T. Miceli, Argyll Equities, LLC, Argyll Biotechnologies, LLC, Padmore Holdings, LTD., Argyll Aviation, LLC, and SW Argyll Investments, LLC.

Background

This matter stems from claims arising out of Defendants’ allegedly fraudulent sale of stock. Plaintiff alleges that Defendants Miceli, McClain Sr., and McClain Jr. began defrauding investors through stock sales after working together at an entity known as International Profit Associates (“IPA”) in Illinois.1 Plaintiff alleges that through IPA, McClain Sr. became involved with a public entity known as Nextpath Technologies, and began selling large volumes of stock to investors based on false information for approximately $6,000,000.2 Plaintiff alleges that after McClain Sr.’s [761]*761involvement with Nextpath, McClain Sr., McClain Jr., and Mieeli left IPA and used money from the sale of Nextpath stock to finance the start of a new entity, FIT Management.3

Plaintiff alleges that FIT Management financed the start of an entity known as Argyll Equities, which had the appearance of a legitimate financial/stock lender “but operated more akin to a Ponzi scheme.”4 Plaintiff alleges that Argyll Equities financed the start up of Argyll Biotechnologies, and that Argyll Equities and/or Argyll Biotechnologies financed the start up of Immunosyn.5 Plaintiff asserts that through those entities, Mieeli and McClain Jr. financially control Immunosyn.6

Plaintiff alleges that Argyll Biotechnologies claimed to own, develop, and promote a drug called SF-1019, and that Immunosyn claimed in its SEC filings and website to have the exclusive rights to sell SF-1019.7 Plaintiff alleges that McClain Sr., McClain, Jr., and Mieeli devised a scheme wherein they would associate and befriend persons in local communities and provide them false information to sell Immunosyn stock in exchange for commission and/or gifted stock.8

Plaintiff alleges that McClain Sr. recruited her boyfriend to sell shares of Immunosyn, and that she learned about the drug SF-1019 from him.9 Plaintiff, who suffers from a neurological disorder, alleges that after learning of the drug, she called McClain Sr. from Florida to ask if it could be used to treat her illness.10 Plaintiff asserts that McClain Sr. informed her that the drug would help her condition and that he would send her some vials for a doctor to administer.11 He also allegedly informed her that SF-1019 had FDA approval in Utah.12 Plaintiff states that during the call she asked if she could purchase some of Immunosyn’s stock and McClain Sr. told her that she could.13 Plaintiff asserts that she understood that McClain Sr. worked for Argyll Biotechnologies and that his family owned the company.14

Plaintiff alleges that in December 2006 she telephoned McClain Sr. from Florida and informed him that she intended to sell her condo for $80,000 and that she would like to invest the money in order to obtain [762]*762enough money to buy another home.15 She claims that she sought advice from McClain Sr. on investing this money in Immunosyn and he told her that she could buy shares at $1 per share and that Immunosyn was soon going public on the NASDAQ at $15 per share.16 Plaintiff alleges that McClain Sr. told her that if she sent him the $80,000 he would send her the stock before it went public and that she would “become a millionaire” from this investment.17 Plaintiff states that she informed McClain Sr. that the $80,000 was all the money she had in the world and that he told her the money was “guaranteed safe.”18

Plaintiff alleges that during phone calls with McClain Sr. in December 2006 and January 2007, McClain Sr. told Plaintiff that the stock was coming from his family trust.19 Plaintiff alleges that this information was false and that the stock actually came from another entity known as Pad-more Holdings, that is partly owned by McClain Sr., McClain Jr., and Miceli.20 Plaintiff states that in January 2007, she sent $80,000 to the bank account of McClain Sr.’s mother.21 Plaintiff alleges that McClain Sr. received Plaintiffs $80,000 prior to Immunosyn going public, but that he did not send her the stock certificates until January or February 2008.22 Plaintiff alleges that McClain Sr. told her that he did not send her the shares right away because he did not want her to sell them on the open market.23 By the time Plaintiff received the stock, Immunosyn had gone public at $15 per share but had significantly decreased in value.24 Upon receipt of the stock, Plaintiff sold some shares immediately because she was desperate for money.25 However, Plaintiff alleges she retained the majority of her shares because McClain Sr. told her not to sell her stock because it would go back to $15 per share after SF-1019 received nation-wide approval by the FDA and was approved for use in Malaysia.26 Plaintiff held on to the stock but it continued to decline in value.27 Plaintiff finally sold her shares on the OTC for $0.12 per share.28 Plaintiff asserts that the stock was never listed on the NASDAQ and never received FDA approval anywhere.29 She purports to have lost $65,000.30

Plaintiff filed suit in this Court alleging that the Defendants, personally, through agents, and through other entities that they control, engaged in false and misleading promotion of Immunosyn stock, for financial gain, to the detriment of others from April 2007 through the present total[763]*763ing more than $14,000,000.31 Plaintiff further alleges that McClain Sr., McClain Jr., and Miceli control the corporate Defendants and have purposefully stripped some of them of assets, regularly transferred funds between entities, failed to segregate personal assets from business assets, and failed to maintain corporate formalities.

Procedural History

On December 7, 2010, Rabin filed a complaint against Douglas McClain Sr, Argyll Biotechnologies, and James Miceli for violation of the Securities Exchange Act, fraud and fraud in the inducement, breach of contract, violation of the Racketeer Influenced and Corrupt Organizations Act (RICO), conspiracy to violate RICO, and civil conspiracy. (Docket No. 1). Plaintiff filed an amended complaint on February 24, 2011, adding Padmore Holdings as a defendant. (Docket No. 3). On May 3, 2011, the Defendants filed answers. (Docket Nos. 8-11). On June 14, 2011, Plaintiff filed a Second Amended Complaint adding Douglas McClain Jr. as a defendant. (Docket No. 30). The defendants filed timely answers to Plaintiffs Second Amended Complaint. (Docket Nos. 42-46).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
881 F. Supp. 2d 758, 2012 U.S. Dist. LEXIS 58441, 2012 WL 1448107, Counsel Stack Legal Research, https://law.counselstack.com/opinion/rabin-v-mcclain-txwd-2012.